Filing Flows › Usana Health Sciences (USNA) › Q2 2026 › vs Q1 2026
Usana Health Sciences (USNA) Q2 2026 vs Q1 2026 (quarter over quarter)
Usana Health Sciences's revenue fell $26.9M (-11%) from $250M in Q1 2026 to $223M in Q2 2026.
Usana Health Sciences, Q2 2026: revenue $223M (-5% year over year), operating margin -9.0%, net loss $28.0M, operating cash flow $23.3M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 9.0% | 2.8% | +6.2 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $223M | $250M | −$26.9M | -11% |
| Other income, net | $1.1M | $1.6M | −$495K | -31% |
| Net loss | $28.0M | −$7.0M | $34.9M | — |
| Costs & expenses | $252M | $252M | $511K | +0.2% |
| Operating costs | $243M | $236M | $6.9M | +3% |
| Income tax | $9.1M | $8.5M | $545K | +6% |
| Cost of revenue | $48.3M | $59.4M | −$11.1M | -19% |
| SG&A | $82.3M | $88.3M | −$5.9M | -7% |
| Other operating costs | $113M | $88.7M | $24.0M | +27% |
| Operating cash sources | $51.3M | $2.8M | $48.5M | 18× |
| Depreciation & amortization | $7.7M | $8.3M | −$603K | -7% |
| Share-based compensation | $3.4M | $3.5M | −$50K | -1% |
| Working capital & other | $40.2M | −$8.9M | $49.1M | — |
| Net loss absorbed | $28.0M | −$7.0M | $34.9M | — |
| Operating cash flow | $23.3M | $9.8M | $13.6M | +139% |
| Free cash flow (OCF − capex) | $20.2M | $7.1M | $13.1M | +183% |
| Capital expenditures | $3.2M | $2.6M | $510K | +19% |
Questions
How much did Usana Health Sciences's revenue grow quarter over quarter in Q2 2026?
Usana Health Sciences's revenue fell $26.9M (-11%) from $250M in Q1 2026 to $223M in Q2 2026.